Literature DB >> 29445068

Lower Plasma Levels of IL-35 in Patients with Primary Biliary Cirrhosis.

Tengda Li1, Yuanlan Huang2, Peng Liu1, Yun Liu3, Jie Guo3, Weiwei Zhang3, Mingli Gu3, Cheng Qian4, Anmei Deng1.   

Abstract

Primary biliary cirrhosis (PBC) is an autoimmune liver disease. Its histological characteristics, such as progressive intrahepatic bile duct destruction, cholestasis, and liver cirrhosis, are caused by the body's autoimmune disorders. Interleukin (IL)-35 has two subunits (p35 and Ebi3) and is a member of the IL-12 family of heterodimeric cytokines. IL-35 has immunosuppressive functions and plays an important role in many autoimmune diseases. In this study, we compared plasma levels of IL-35 and relative mRNA expression levels of p35 and Ebi3 in peripheral blood mononuclear cells (PBMCs) from 70 PBC patients and 70 healthy individuals. The results showed that the relative expression levels of Ebi3 mRNA were lower in PBMCs from PBC patients than in PBMCs from healthy individuals, whereas the levels of p35 mRNA were similar in both groups. Plasma IL-35 concentrations were lower in patients with PBC than in healthy individuals. Plasma levels were higher in PBC patients at an advanced stage compared to patients at an early stage. Variable plasma levels with different stages were also found in transforming growth factor beta (TGF-β), which is mainly produced by regulatory T cells (Tregs). IL-35 and TGF-β levels were positively correlated with each other, and IL-35 was capable of promoting the inhibitory functions of Tregs in PBC patients at both the early and late stages of disease. Lower plasma IL-35 levels were accompanied by higher levels of typical clinical parameters, such as alkaline phosphatase, or of proinflammatory cytokines, such as interferon-gamma (IFN-γ), in PBC patients (P < 0.05 for each). We propose that IL-35 may be involved in the pathogenesis of PBC and could be a potential biomarker for diagnosing this disease.

Entities:  

Keywords:  IFN-γ; IL-23; IL-35; TGF-β; primary biliary cirrhosis

Mesh:

Substances:

Year:  2018        PMID: 29445068     DOI: 10.1620/tjem.244.123

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  4 in total

Review 1.  Interplay between Mast Cells and Regulatory T Cells in Immune-Mediated Cholangiopathies.

Authors:  Natalia M Krajewska; Rémi Fiancette; Ye H Oo
Journal:  Int J Mol Sci       Date:  2022-05-24       Impact factor: 6.208

2.  Kupffer Cells Regulate Natural Killer Cells Via the NK group 2, Member D (NKG2D)/Retinoic Acid Early Inducible-1 (RAE-1) Interaction and Cytokines in a Primary Biliary Cholangitis Mouse Model.

Authors:  Hai-Yan Fu; Wei-Min Bao; Cai-Xia Yang; Wei-Ju Lai; Jia-Min Xu; Hai-Yan Yu; Yi-Na Yang; Xu Tan; Ajay Kumar Gupta; Ying-Mei Tang
Journal:  Med Sci Monit       Date:  2020-06-29

Review 3.  The Role of IL-35 in the Pathophysiological Processes of Liver Disease.

Authors:  Shuang Hu; Pan-Pan Lian; Ying Hu; Xing-Yu Zhu; Shao-Wei Jiang; Qiang Ma; Liang-Yun Li; Jun-Fa Yang; Li Yang; Hai-Yue Guo; Hong Zhou; Chen-Chen Yang; Xiao-Ming Meng; Jun Li; Hai-Wen Li; Tao Xu; Huan Zhou
Journal:  Front Pharmacol       Date:  2021-01-21       Impact factor: 5.810

4.  Abnormal Expression of ERα in Cholangiocytes of Patients With Primary Biliary Cholangitis Mediated Intrahepatic Bile Duct Inflammation.

Authors:  Hui Cao; Bukun Zhu; Yao Qu; Wei Zhang
Journal:  Front Immunol       Date:  2019-12-05       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.